About the Company
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition (for repricing), manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs), primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRGO News
Perrigo’s Strategic Divestiture Prompts Buy Rating from Analyst Susan Anderson
In a report released yesterday, Susan Anderson from Canaccord Genuity maintained a Buy rating on Perrigo Company (PRGO – Research ...
Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” first quarter 2024 investor ...
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care ...
Esteve Healthcare To Buy Perrigo's HRA Pharma Rare Diseases Business For Up To EUR 275 Mln
Perrigo Company plc (PRGO), a provider of Consumer Self-Care Products, Thursday said pharmaceutical company Esteve Healthcare, S.L.
perrigo €275m unit sale to esteve healthcare
In a significant move in the healthcare sector, Perrigo Co. PLC announced on Thursday its decision to divest its HRA Pharma ...
Perrigo (PRGO) Price Target Increased by 5.19% to 41.31
The average one-year price target for Perrigo (NYSE:PRGO) has been revised to 41.31 / share. This is an increase of 5.19% ...
Perrigo Company plc (PRGO) Stock Experiences -1.35% Monthly Change
PRGO stock has gone down by -7.01%, with a monthly decline of -1.35% and a quarterly plunge of -9.21%. The volatility ratio for the week is 2.37%, and the volatility levels for the last 30 days are 2.
Alopecia Treatment Market Qualitative Symphony Crafting Harmonious Insights through Focus Groups
Alopecia Treatment Market is valued approximately at USD 2.6 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 9.5 % over the forecast period 2020-2027. The Alopecia, ...
Clinical Nutrition Market Qualitative Edge Elevating Research Outcomes with Focus Groups
Clinical Nutrition Market is valued at approximately USD 33 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 5.3% over the forecast period 2020-2027. Clinical ...
Global Tinea Pedis Treatment Market Set to Skyrocket, Reaching US$ 2.24 Billion by 2032
Tinea Pedis Treatment Market is projected to an impressive US$ 2.24 billion by the end of 2032, reflecting a remarkable CAGR ...
AGW-Mental Wellbeing 2024 - Large-size companies
To spotlight the organizations prioritizing the mental well-being of their employees, Newsweek has partnered with data researcher Plant-A for the inaugural ranking of America's Greatest Workplaces for ...
Perrigo Company plc: Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Mill ...
Loading the latest forecasts...